INTERLEUKIN-10 REDUCES MORTALITY FROM SEVERE PERITONITIS IN MICE

被引:85
作者
KATO, T
MURATA, A
ISHIDA, H
TODA, H
TANAKA, N
HAYASHIDA, H
MONDEN, M
MATSUURA, N
机构
[1] NATL UTANO HOSP, DEPT INTERNAL MED, KYOTO, JAPAN
[2] NATL UTANO HOSP, CLIN RES CTR, KYOTO, JAPAN
[3] WAKAYAMA MED COLL, DEPT PATHOL 2, WAKAYAMA, JAPAN
关键词
D O I
10.1128/AAC.39.6.1336
中图分类号
Q93 [微生物学];
学科分类号
071005 [微生物学]; 100705 [微生物与生化药学];
摘要
Interleukin 10 (IL-10) is known to suppress the induction of proinflammatory cytokines such as tumor necrosis factor (TNF) and IL-1 and is itself induced by monocytes and macrophages during sepsis. We studied the therapeutic efficacy of IL-10 by testing its effect on the survival rate in the murine cecal ligation-and-puncture (CLP) model. Administration of 1 mu g or more of recombinant murine IL-10 6 h after induction of sepsis decreased lethality in septic mice significantly and also suppressed the elevation of circulating TNF after sepsis. However, treatment with the same dose of IL-10 simultaneously or 6 h before induction of CLP had no effect on survival, and treatment with anti-TNF antibody after induction of CLP had no effect on the survival rate. These data suggest that cytokine modulation with IL-10 is a potential candidate for the treatment of sepsis and sepsis-related multiple organ failure.
引用
收藏
页码:1336 / 1340
页数:5
相关论文
共 32 条
[1]
STRATEGIES OF ANTICYTOKINE MONOCLONAL-ANTIBODY DEVELOPMENT - IMMUNOASSAY OF IL-10 AND IL-5 IN CLINICAL-SAMPLES [J].
ABRAMS, JS ;
RONCAROLO, MG ;
YSSEL, H ;
ANDERSSON, U ;
GLEICH, GJ ;
SILVER, JE .
IMMUNOLOGICAL REVIEWS, 1992, 127 :5-24
[2]
ALEXANDER HR, 1992, SURGERY, V112, P188
[3]
BAUE AE, 1992, ARCH SURG-CHICAGO, V127, P1451
[4]
INTERLEUKIN-10 PROTECTS MICE AGAINST STAPHYLOCOCCAL-ENTEROTOXIN B-INDUCED LETHAL SHOCK [J].
BEAN, AGD ;
FREIBERG, RA ;
ANDRADE, S ;
MENON, S ;
ZLOTNIK, A .
INFECTION AND IMMUNITY, 1993, 61 (11) :4937-4939
[5]
MACROPHAGE DEACTIVATION BY INTERLEUKIN-10 [J].
BOGDAN, C ;
VODOVOTZ, Y ;
NATHAN, C .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 174 (06) :1549-1555
[6]
DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ .
CHEST, 1992, 101 (06) :1644-1655
[7]
INTERLEUKIN-10 (IL-10) INHIBITS THE RELEASE OF PROINFLAMMATORY CYTOKINES FROM HUMAN POLYMORPHONUCLEAR LEUKOCYTES - EVIDENCE FOR AN AUTOCRINE ROLE OF TUMOR-NECROSIS-FACTOR AND IL-1-BETA IN MEDIATING THE PRODUCTION OF IL-8 TRIGGERED BY LIPOPOLYSACCHARIDE [J].
CASSATELLA, MA ;
MEDA, L ;
BONORA, S ;
CESKA, M ;
CONSTANTIN, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (06) :2207-2211
[8]
ESKANDARI MK, 1992, J IMMUNOL, V148, P2724
[9]
FIORENTINO DF, 1991, J IMMUNOL, V147, P3815
[10]
RECOMBINANT HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST IN THE TREATMENT OF PATIENTS WITH SEPSIS SYNDROME - RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
FISHER, CJ ;
DHAINAUT, JFA ;
OPAL, SM ;
PRIBBLE, JP ;
BALK, RA ;
SLOTMAN, GJ ;
IBERTI, TJ ;
RACKOW, EC ;
SHAPIRO, MJ ;
GREENMAN, RL ;
REINES, HD ;
SHELLY, MP ;
THOMPSON, BW ;
LABRECQUE, JF ;
CATALANO, MA ;
KNAUS, WA ;
SADOFF, JC ;
ASTIZ, M ;
CARPATI, C ;
BONE, RC ;
FREIDMAN, B ;
MURE, AJ ;
BRATHWAITE, C ;
SHAPIRO, E ;
MELHORN, L ;
TAYLOR, R ;
KEEGAN, M ;
OBRIEN, J ;
SCHEIN, R ;
PENA, M ;
WASSERLOUF, M ;
OROPELLO, J ;
BENJAMIN, E ;
DELGUIDICE, R ;
EMMANUEL, G ;
LIE, T ;
ANDERSON, L ;
MARSHALL, J ;
DEMAJO, W ;
ROTSTEIN, O ;
FOSTER, D ;
ABRAHAM, E ;
MIDDLETON, H ;
PERRY, C ;
LEVY, H ;
FRY, DE ;
SIMPSON, SQ ;
CROWELL, RE ;
NEIDHART, M ;
STEVENS, D .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (23) :1836-1843